TNF in type 1 diabetics and glucose control and cardiovascular risk – (08-21-00)



TNF in type 1 diabetics and glucose control and cardiovascular risk

This study points to TNF-alpha as a contributor to the damage done to the pancreas in Type I diabetes. Recall that TNF inhibitors are the new rheumatoid arthritis and now Crohn’s disease drugs. As research gets more and more specific, I truly believe that we will come to find really only a few abnormalities causing most of man’s chronic diseases. TNF-alpha is a perfect example.

Journal of Internal Medicine 248 (1), 67-76 The cytokine TNF-a reveals a complex relationship with diabetes. It is involved in beta-cell damage leading to type 1 diabetes, causes insulin resistance associated with obesity and is of influence in the formation of atherosclerotic vascular lesions. We were interested in the possible association of this cytokine with metabolic control and cardiovascular risk factors in patients with type 1 diabetes. Our data indicate that TNF-a plasma levels are increased in type 1 diabetes mellitus and reveal a significant association with metabolic long-term control parameters, HbA1c and fructosamine for glycaemic control, and HDL cholesterol for triglyceride metabolism, as well with lipid peroxidation.

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Category: Type 1 Diabetes
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”